Abstract:Oncolytic peptides represented potential novel candidates for anticancer treatments especially drug-resistant cancer cell lines. One of the most promising and extensively studied is LTX-315, which is considered as the first in class oncolytic peptide and has entered phase I/II clinical trials. Nevertheless, the shortcomings including poor proteolytic stability, moderate anticancer durability and high synthesis costs may hinder the widespread clinical applications of LTX-315. In order to reduce the synthesis costs, as well as develop derivatives possessing both high protease-stability and durable anticancer efficiency, twenty LTX-315-based derived-peptides were designed and efficiently synthesized. Especially, through solid-phase S-alkylation, as well as the optimized peptide cleavage condition, the derived peptides could be prepared with drastically reduced synthesis cost. The in vitro anticancer efficiency, serum stability, anticancer durability, anti-migration activity, and hemolysis effect were systematically investigated. It was found that derived peptide MS-13 exhibited comparable anticancer efficiency and durability to those of LTX-315. Strikingly, the D-type peptide MS-20, which is the enantiomer of MS-13, was demonstrated to possess significantly high proteolytic stability and sustained anticancer durability. In general, the cost-effective synthesis and stability-guided structural optimizations were conducted on LTX-315, affording the highly hydrolysis resistant MS-20 which possessed durable anticancer activity. Meanwhile, this study also provided a reliable reference for the future optimization of anticancer peptides through the solid-phase S-alkylation and L-type to D-type amino acid substitutions.

\Development of sulfonium tethered peptides conjugated with HDAC inhibitor to improve selective toxicity for cancer cells

Intracellular Restructured Reduced Glutathione-Responsive Peptide Nanofibers for Synergetic Tumor Chemotherapy

Data from Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells in Vivo

Histone Deacetylase‐Triggered Self‐Immolative Peptide‐Cytotoxins for Cancer‐Selective Drug Delivery

Rational design of self-assembled mitochondria- targeting lytic peptide conjugates with enhanced tumor selectivity.

Tumor Cells-Specific Targeting Delivery Achieved by A54 Peptide Functionalized Polymeric Micelles

Modulating Protein Protein Interactions in Vivo Via Peptide-Lanthanide-Derived Nanoparticles for Hazard-Free Cancer Therapy

Design of Cell-Specific Targeting Peptides for Cancer Therapy

Rational design of a new short anticancer peptide with good potential for cancer treatment

Improved Breast Cancer Cell-Specific Intracellular Drug Delivery and Therapeutic Efficacy by Coupling Decoration with Cell Penetrating Peptide and SP90 Peptide.

Correction to "Structure-Based Design, Optimization, and Evaluation of Potent Stabilized Peptide Inhibitors Disrupting MTDH and SND1 Interaction".

Efficient synthesis and anticancer evaluation of spider toxin peptide LVTX-8-based analogues with enhanced stability

Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy

Synthesis and structural optimization of oncolytic peptide LTX-315

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

Design and synthesis of TH19P01-Camptothecin based hybrid peptides inducing effective anticancer responses on sortilin positive cancer cells

Development of a Lytic Peptide Derived from BH3-only Proteins

Synergistic Effect of Reduced Polypeptide Micelle for Co-Delivery of Doxorubicin and Trail Against Drug-Resistance in Breast Cancer

Intracellular Delivery of Stabilized Peptide Blocking MTDH-SND1 Interaction for Breast Cancer Suppression

A Synthetic Peptide Mediated Active Targeting of Cisplatin Liposomes to Tie2 Expressing Cells.

Optimal Design of Novel Functionalized Nanoconjugates Based on Polymalic Acid for Efficient Tumor Endocytosis with Enhanced Anticancer Activity.